Rezera

Rezera, formely Nodthera, is a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases driven by the NLRP3 inflammation pathway. The Company’s lead program, ruvonoflast (f/k/a NT-0796), completed its Phase 2 RESOLVE-1 and RESOLVE-2 trials. The Company is also advancing trabzanoflast (f/k/a NT-0150) for treatment of neurologic diseases.

Rezera is headquartered in Boston, Massachusetts, with an R&D base in Cambridge, UK.